Organon & Co (OGN) FinancialsOGNOrganon & Co

Organon & Co. (OGN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Women’s Health, accounting for 26.9% of total sales, equivalent to $419.00M. Other significant revenue streams include Cardiovascular and Non-Opioid Pain, Bone and Dermatology. Understanding this composition is critical for investors evaluating how OGN navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Organon & Co. maintains a gross margin of 54.36%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.51%, while the net margin is 6.93%. These profitability ratios, combined with a Return on Equity (ROE) of 24.04%, provide a clear picture of how effectively OGN converts its operational activities into shareholder value.

In the context of the broader market, OGN competes directly with industry leaders such as VKTX and GPCR. With a market capitalization of $3.60B, it holds a significant position in the sector. When comparing efficiency, OGN's gross margin of 54.36% stands against VKTX's N/A and GPCR's N/A. Such benchmarking helps identify whether Organon & Co. is trading at a premium or discount relative to its financial performance.

Organon has shown a gross margin of 54.36% in Q2 2026, indicating solid profitability. However, its net income has been inconsistent, with a recent dip into negative territory.